Thousand Oaks, CA, United States of America

Kyle Quasdorf

USPTO Granted Patents = 7 

 

Average Co-Inventor Count = 9.1

ph-index = 5

Forward Citations = 60(Granted Patents)


Company Filing History:


Years Active: 2021-2025

Loading Chart...
Loading Chart...
7 patents (USPTO):

Title: The Innovative Journey of Kyle Quasdorf

Introduction

Kyle Quasdorf is a notable inventor based in Thousand Oaks, CA (US). He has made significant contributions to the field of pharmaceuticals, holding a total of 7 patents. His work focuses on the synthesis of complex compounds that have potential therapeutic applications.

Latest Patents

One of his latest patents is titled "Process for preparing 7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione." This patent outlines a detailed process for preparing a compound that involves several steps, including the admixing of specific amines and reactive compounds in an organic solvent. Another significant patent is related to the "Synthesis of omecamtiv mecarbil," which details the synthesis of omecamtiv mecarbil dihydrochloride hydrate and various intermediates.

Career Highlights

Kyle has worked with prominent companies in the pharmaceutical industry, including Amgen Inc. and Cytokinetics, Inc. His experience in these organizations has allowed him to develop innovative solutions and contribute to groundbreaking research in drug development.

Collaborations

Throughout his career, Kyle has collaborated with talented individuals such as Sebastien Caille and Bin Peter Quan. These partnerships have fostered a creative environment that encourages the exchange of ideas and advancements in their respective fields.

Conclusion

Kyle Quasdorf's contributions to the field of pharmaceuticals through his innovative patents and collaborations highlight his dedication to advancing medical science. His work continues to inspire future inventors and researchers in the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…